Literature DB >> 31444400

TP53 deficiency permits chromosome abnormalities and karyotype heterogeneity in acute myeloid leukemia.

Anna Cazzola1, Christin Schlegel1, Ilka Jansen1, Tilmann Bochtler1,2,3, Anna Jauch4, Alwin Krämer5,6.   

Abstract

Abnormal karyotypes are common in cancer cells and frequently observed in acute myeloid leukemia (AML), in which complex karyotype aberrations are associated with poor prognosis. How exactly abnormal karyotypes arise and are propagated in AML is unclear. TP53 mutations and deletions are frequent in complex karyotype AML, suggesting a role of TP53 alterations in the development of chromosome abnormalities. Here, we generated isogenic TP53-knockout versions of the euploid AML cell line EEB to investigate the impact of TP53 on karyotype stability. We show that chromosome abnormalities spontaneously arise in TP53-deficient cells. Numerical aneuploidy could, to some extent, be propagated in a TP53-proficient setting, indicating that it does not necessarily trigger TP53 activation. In contrast, tolerance to structural chromosome aberrations was almost entirely restricted to TP53-knockout clones, all of which were able to continue proliferation in the presence of damaged DNA. Mechanistically, as a source of chromosome aberrations, limited numerical but not structural chromosomal instability was tolerated by TP53-wildtype cells. In contrast, structural instability was found only in TP53-knockout cells. Together, in myeloid cells TP53 loss allows for the development of complex karyotype aberrations and karyotype heterogeneity by perpetuation of chromosome segregation errors.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31444400     DOI: 10.1038/s41375-019-0550-5

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  1 in total

1.  Targeted inactivation of p53 in human cells does not result in aneuploidy.

Authors:  Fred Bunz; Christine Fauth; Michael R Speicher; Annie Dutriaux; John M Sedivy; Kenneth W Kinzler; Bert Vogelstein; Christoph Lengauer
Journal:  Cancer Res       Date:  2002-02-15       Impact factor: 12.701

  1 in total
  5 in total

1.  TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML.

Authors:  Jayakumar Vadakekolathu; Catherine Lai; Stephen Reeder; Sarah E Church; Tressa Hood; Anbarasu Lourdusamy; Michael P Rettig; Ibrahim Aldoss; Anjali S Advani; John Godwin; Matthew J Wieduwilt; Martha Arellano; John Muth; Tung On Yau; Farhad Ravandi; Kendra Sweet; Heidi Altmann; Gemma A Foulds; Friedrich Stölzel; Jan Moritz Middeke; Marilena Ciciarello; Antonio Curti; Peter J M Valk; Bob Löwenberg; Ivana Gojo; Martin Bornhäuser; John F DiPersio; Jan K Davidson-Moncada; Sergio Rutella
Journal:  Blood Adv       Date:  2020-10-27

Review 2.  Chromosomal Instability in Acute Myeloid Leukemia.

Authors:  Mateus de Oliveira Lisboa; Paulo Roberto Slud Brofman; Ana Teresa Schmid-Braz; Aline Rangel-Pozzo; Sabine Mai
Journal:  Cancers (Basel)       Date:  2021-05-28       Impact factor: 6.639

3.  ZMYND8 Expression in Breast Cancer Cells Blocks T-Lymphocyte Surveillance to Promote Tumor Growth.

Authors:  Yong Wang; Maowu Luo; Yan Chen; Yijie Wang; Bo Zhang; Zhenhua Ren; Lei Bao; Yanan Wang; Jennifer E Wang; Yang-Xin Fu; Weibo Luo; Yingfei Wang
Journal:  Cancer Res       Date:  2020-11-04       Impact factor: 13.312

4.  Kasumi leukemia cell lines: characterization of tumor genomes with ethnic origin and scales of genomic alterations.

Authors:  Fumio Kasai; Hiroya Asou; Midori Ozawa; Kazuhiko Kobayashi; Hiroyuki Kuramitsu; Motonobu Satoh; Arihiro Kohara; Yasuhiko Kaneko; Machiko Kawamura
Journal:  Hum Cell       Date:  2020-03-16       Impact factor: 4.174

5.  TP53 Expression and Mutational Analysis in Hematological Malignancy in Jeddah, Saudi Arabia.

Authors:  Heba Alkhatabi; Elrashed B Yasin; Zeenat Mirza; Raed Alserihi; Raed Felimban; Aisha Elaimi; Manal Shaabad; Lina Alharbi; Hameeda Ahmed; Abdulrahman M Alameer; Abdullah Ebraheem Mathkoor; Ahmed Salleh Barefah
Journal:  Diagnostics (Basel)       Date:  2022-03-16
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.